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Integrating clinical, molecular, proteomic and histopathological data within the tissue
context: tissunomics
Malignant tumours show a marked degree of morpho-
logical, molecular and proteomic heterogeneity. This
variability is closely related to microenvironmental fac-
tors and the location of the tumour. The activation of
genetic alterations is very tissue-dependent and only
few tumours have distinct genetic alterations. Impor-
tantly, the activation state of proteins and signaling
factors is heterogeneous in the primary tumour and in
metastases and recurrences. The molecular diagnosis
based only on genetic alterations can lead to treat-
ments with unpredictable responses, depending on the
tumour location, such as the tumour response in mela-
nomas versus colon carcinomas with BRAF mutations.
Therefore, we understand that the correct evaluation
of tumours requires a system that integrates both mor-
phological, molecular and protein information in a
clinical and pathological context, where intratumoral
heterogeneity can be assessed. Thus, we propose the
term ‘tissunomics’, where the diagnosis will be contex-
tualised in each tumour based on the complementation
of the pathological, molecular, protein expression,
environmental cells and clinical data.
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General Background of Tumour Pathology
Despite constant progress in cancer research, mortality
rates remain high.1,2 Five-year survival is greater than
80% for carcinoma of the breast, prostate and bladder,
cutaneous melanoma and testicular and thyroid
tumours, but less than 10% in pancreatic, liver, oeso-
phageal, lung and stomach tumours and glioblastoma.
If we focus on tumour stage, we observe that in luminal
breast cancer, expected survival is greater than 90% in
patients without metastases at diagnosis and less than
25% in patients with disseminated disease.3 With this in
mind, early detection, histological typing and extent of
dissemination are critical for treatment success. Further-
more, the more than 250 tumour types and hundreds
of subtypes, on a background of thousands of genetic,
epigenetic and microRNA alterations,4–6 highlight the
importance of precise tumour sample evaluation in
deciding the most appropriate clinical treatment.
Inter- and intratumour heterogeneity (ITH)7,8 act
as a critical barrier to improving therapeutics: most
of the targets and biomarkers approved by the United
States Food and Drug Administration are not
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expressed uniformly throughout tumour tissue; for
example, the human epidermal growth factor recep-
tor 2 (HER2) in gastric adenocarcinoma,9,10 proges-
terone and oestrogen receptors in breast tumours
(considered positive when detected in 1% of tumour
cells)11 and EML4–ALK translocation in lung adeno-
carcinoma (threshold of 15%),12 among others.13,14
Current Situation and Challenges
W H Y A R E M A L I G N A N T T U M O U R S
H E T E R O G E N E O U S ?
The paradigm of cancer as a genetic disease has
existed since the early 1970s. For the last 50 years,
cancer has been explained according to the somatic
mutation theory (SMT),15 which states that genetic
mutations accumulate in cells by inducing clonal
expansion. Following Darwinian-type evolution, an ini-
tial clone accumulates multiple mutations, resulting in
malignant transformation characterised by growth
independence and resistance to apoptosis. These clones
have trunk and branch mutations, and may also have
driver and passenger mutations.16–18 During tumour
progression and after chemotherapy or radiotherapy,
genetic alterations accumulate to select for the best-
adapted clone. Molecular heterogeneity has been
described in renal adenocarcinoma, breast cancer and
glioblastoma, among others.19 It is thought that these
clones with greater proliferative advantages and resis-
tance to local stresses then predominate.20–24
Other theories include the tissue organisation field
theory (TOFT), which postulates that neoplasia arises
from a local tissue disorder and may be due to a defect
in interaction between cells and other tissue compo-
nents,15,25–27 where epigenetic or genetic changes
affect both epithelial and stromal cells in multiple loca-
tions. Grouping together the evidence for these theo-
ries, it has been demonstrated that (i) many
spontaneous somatic mutations accumulate in cells
during their lifetime, (ii) oncogenes and tumour sup-
pressor genes play a critical role in cancer development
and (iii) environmental factors trigger cancer onset
and progression.15 Regarding field cancerisation, some
authors have proposed that cancer is a tissue disorder
with similarities to abnormal embryonic develop-
ment,15,25 while others propose that cancer is a con-
sortium of clones and local factors.28 It is understood
that a single clone cannot harbour all the genetic alter-
ations required for the invasive and metastatic tumour
phenotype and that several clones acquire malignant
properties that, synergistically, allow cells to grow,
invade and metastasise. This consortium of tumour cell
clones and microenvironment cells includes leucocytes,
lymphocytes, fibroblasts and endothelial cells. A mini-
mum number of cells is also required for a clone to be
biologically viable – a phenomenon known as the
Allee effect. This clonal cooperation has been proposed
in pancreatic and breast cancer and melanoma and for
circulating tumour cell (CTC) clusters.29–33
S O M E O N C O G E N I C A L T E R A T I O N S A R E
T I S S U E - S P E C I F I C
Certain genetic alterations are only observed in the con-
text of specific cell or tissue types;34 for example,
alterations in the APC gene in colorectal cancer, CDH1
(E-cadherin) in gastric carcinoma, the VHL gene in
renal carcinoma or BCR/ABL in leukaemia.35,36 These
specific genetic alterations demonstrate that tissue type
plays a role, which is currently not well understood and
is under intensive investigation. The higher incidence
of certain somatic mutations in some cell types might
be explained by a cell- or tissue-specific chromosome
disposition during interphase. This, along with epige-
netic imprinting, may serve as a mechanism of gene
regulation and allow differential access of carcinogens
to certain DNA regions, resulting in a higher probability
of mutations and specific rearrangements in some cells
but not others. Similarly, the accessibility of certain
chromosomal regions might explain cell-type-specific
chromosomal translocations such as BCR/ABL in leuco-
cytes or VHL mutations in renal cell carcinoma.37,38
Some mutations and genetic alterations are uniformly
present in the entire organism, such as germline muta-
tions, BRCA1 and BRCA2, VHL in Von Hippel Lindau
syndrome and as many as 30 others, but they are usu-
ally only associated with tumours in specific tissues,
such as BRCA1/2 in breast and ovarian tumours.39
This clearly indicates that driver, trigger or passenger
mutations only exert an effect in certain tissues.
S O M E H I S T O P A T H O L O G I C A L F E A T U R E S S U G G E S T
O N C O G E N I C A L T E R A T I O N S
The specific morphological patterns observed in human
tumours have helped to identify distinct genetic
changes: for example, characteristic chromosomal
translocations have been identified in desmoplastic
round-cell tumours, clear-cell sarcoma, synovial sar-
coma and rhabdoid tumours.40–42 Moreover, a simple
haematoxylin and eosin stain can indicate the presence
of a number of hereditary tumours with specific genetic
alterations, such as medullary thyroid carcinoma, mul-
tiple endocrine neoplasia (MEN),43,44 the cribriform-
morular variant of papillary thyroid carcinoma,45
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familial adenomatous polyposis,46 medullary breast car-
cinoma, familial breast cancer associated with specific
BRCA1 mutations,47 renal carcinoma, associated with
SDHB mutations which shows flocculent cytoplasmic
vacuoles,48,49 hereditary leiomyomatosis and renal cell
cancer syndrome,50 and sebaceous lesions associated
with Muir–Torre syndrome in colon cancer.51,52 Thus,
hereditary cancer predisposition syndromes can be iden-
tified by immunohistochemistry, which has emerged as
a cost-effective strategy (see Table 1).53
In contrast, other molecular alterations have been
associated with tumours whose morphological charac-
teristics are strikingly distinct, such as (i) the ETV6–
NTRK3 translocation, detected in diverse tumour types
including infantile fibrosarcoma, cellular mesoblastic
nephroma and secretory breast carcinoma;54 (ii)
translocation affecting the ALK gene, in anaplastic
large-cell lymphoma, lung adenocarcinoma, inflamma-
tory myofibroblastic tumour and others;55 (iii) EWSR1–
CREB1 translocation in clear-cell sarcoma and
angiomatoid fibrous histiocytoma;56 and (iv) BRAF
mutations and translocations in benign nevi, malignant
melanoma, colon adenocarcinoma, glioblastomas and
pilocytic astrocytoma, as well as others.57
Thus, the association between genetic alterations
and specific tumour types is not clear, but some
histopathological patterns suggest certain genetic
alterations and hereditary tumour syndromes.
Problems and Barriers
B I A S A N D L I M I T A T I O N S O F M O L E C U L A R
C L A S S I F I C A T I O N A N D S O M A T I C T H E O R Y
Intratumour heterogeneity and pitfalls in the
interpretation of oncogenic factors in small biopsies
Intratumour heterogeneity at the morphological,
molecular and proteomic level is seen in most
tumours. In melanoma, intratumour heterogeneity of
BRAF mutations is described in more than 10% of
cases11,13,14,58 so, depending on the zone biopsied
within a tumour, the determination of BRAF muta-
tions may be wild-type or mutant, with clear clinical
implications (see Figure 1). This example can be
extended to other targets and biomarkers, such as
EGFR mutations in non-small cell lung cancer
(NSCLC),59 ALK rearrangement and others.60
Molecular and preneoplastic changes in the context of the
adjacent tissue: field cancerisation
Until now, tumour diagnosis has focused on histologi-
cal and molecular features, yet it is well known that
the surrounding cells and other areas of the tissue
may display premalignant histological changes such
as dysplasia; furthermore, many genetic alterations
occur without cytological changes. These environ-
mental changes can affect tumour progression by
exerting evolutionary pressure on tumour cells and
ultimately determining which mutations are
selected.27 Examples of preneoplastic histological
lesions include dysplasia (cytological atypia, large
hyperchromatic nuclei or nucleoli) and in-situ carcino-
mas (with no basement membrane invasion), which
are observed in most carcinomas. It is noteworthy
that some early neoplastic lesions such as colon ade-
nomas and skin naevi are polyclonal. Progression to
cancer probably involves the accumulation of multiple
field cancerisation driver mutations among synergisti-
cally acting groups of mutations.27 In this regard,
molecular studies of peritumour areas in normal ducts
of the breast or prostate may show a high number of
genetic alterations and driver mutations.61 The clini-
cal meaning of these molecular changes remains
unknown, and further large studies are needed to
establish their correlation with tumour relapse.
Nonetheless, two important conclusions can be
drawn: (i) the study of non-tumour tissue can be rele-
vant in predicting prognosis and risk of second or
multiple neoplasia and (ii) we must be very cautious
making a diagnosis of malignancy based only on
molecular data, as not all mutations in, for example,
driver genes, are directly linked to cancer develop-
ment.
Mixed tumours as an example of the relevance of
integrating molecular features into their morphological
context
Mixed tumours provide the most extreme examples of
intratumour heterogeneity. They are composed of
two or more histological components, each with a dif-
ferent natural history, and are occasionally detected
in every organ of the human body.
In most cases, the two biologically distinct tumour
components are clonally related, and it is thought
that the more aggressive component arises from the
more indolent one and is usually responsible for the
aggressiveness of the tumour. The amount of each
component is also closely related to outcome.
In a small proportion of cases the two components
are not clonally related: they are not true mixed
tumours, but collision tumours in which two distinct
neoplasms have developed independently, with a dif-
ferent natural history.
In a high proportion of mixed tumours, morpholog-
ical appearance correlates with molecular diversity.
For example, mixed endometrioid and serous
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staining in tumoral cells Examples
Chromosomal
translocation
Overexpression of protein encoded
by one of the genes involved in fusion
or chimeric protein encoded by the two
genes involved in fusion. Positive
immunostaining in tumour cells
BCL2 expression in follicular lymphoma
Cyclin D1 expression in mantle cell lymphoma
ALK expression in different tumour cells (anaplastic lymphoma, NSCLC)
NUT expression in NUT midline carcinoma
ERG expression in prostate carcinoma
ROS1 expression in NSCLC
Gene mutation Aberrant subcellular localisation
of antigen or protein
Nuclear translocation of B-catenin in (CRC, desmoid fibromatosis,
cribriform morular variant of PTC)
Cytoplasmic expression of nucleophosmin in AML
Cytoplasmic expression of BRCA1 in BC.
Stabilisation and strong expression
of the protein encoded by
the gene mutated
P53 in different tumour types (high grade serous ovary carcinoma)
Mutation specific antibodies,
the antibody do not recognize the
WT form of the protein (gene)
IDH1 R132H expression in gliomas
EGFR L858R expression in NSCLC
EGFR Del 19 expression in NSCLC
BRAF V600E expression in different tumor types (Melanoma, PTC,
CRC, others.)
Presence or lack of mutation of certain
genes give an overexpression of
certain surrogate markers
LCC without IGH mutation is associate with overexpression of ZAP-70
Gene deletion or
loss of function
Inactivating mutation, deletion or
promoter hypermethylation of gene
gives a loss of protein expression
of the encoded genes
Loss of E-cadherin staining in lobular breast carcinoma
Loss of INI-1 staining in rhabdoid tumor, and epithelioid sarcoma
Loss of staining for any MMR proteins (MLH1, MSH2, MSH6, PMS2) in
HNPCC with MSI
Loss of staining for parafibromin in parathyroid Carcinoma
Loss of staining for Rb in spindle cell /pleomorphic lipoma
Lack of staining for SDHB in hereditary paragangliomas and
gastrointestinal stromal tumor
Loss of PTEN expression in endometrial cancer with PTEN mutation and
Cowden Syndrome
Gene amplification Increase in copy number of gene
gives an overexpression of
the encoded protein
HER2 strong staining in breast and gastric cancer associated with
HER2 amplification
Strong staining for MDM2 or CDK4 associates with 12q14-15
amplification in liposarcoma or well-differentiated osteosarcoma.
Strong MET expression in NSCLC
Adapted from
Chan et al.53.
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carcinomas of the endometrium contain elements
with the microscopic characteristics of endometrioid
and serous carcinoma, and molecular analysis of
microdissected tumour tissue shows that the two
components have a different mutational profile. Other
mixed tumours are ambiguous, and different micro-
scopic features develop in tumour components with
similar molecular alterations, probably as a result of
interaction with the microenvironment.62
In some mixed tumours the microscopic diversity is
extreme. This is the case in biphasic synovial sar-
coma, carcinosarcomas and some mesotheliomas. In
carcinosarcomas (named differently in different
organs: metaplastic carcinoma, sarcomatoid carci-
noma, carcinosarcoma) the malignant epithelial com-
ponent gives rise to mesenchymal elements, and may
even contain fully developed sarcomatoid features,
such as malignant skeletal muscle, cartilage or bone
elements. Integration of the molecular features into
the appropriate microscopic context is essential to
understand these tumours and accurately assess
prognosis.
Cancer-type-independent molecular classification of
therapeutic targets
Currently, precision oncology is based on the exis-
tence of alterations in certain specific therapeutic tar-
gets regardless of tumour location or type. Tumours
with somatic mutations such as BRAF, EGFR or gene
rearrangements such as ALK are considered thera-
peutic options regardless of tumour type or location,
and tumours may even be characterised as BRAFo-
mas or ALKomas. However, some clinical data have
shown that, while BRAF inhibitors are effective in
melanoma, the same inhibitors of the same BRAF
mutations in colorectal cancer induce feedback loops
in signalling pathways that can have a detrimental
effect.63,64 Cell signalling pathways are also highly
regulated, often dependent on numerous positive and
negative feedback loops, which are specific to the cell
type and tumour environment. For this reason,
BRAF inhibition in colorectal cancer indirectly
results in EGFR receptor activation and subsequent
PI3K–Akt pathway activation. Similarly, ALK alter-
ations and their inhibitors do not have the same
clinical response in lung tumours as in neuroblas-
tomas.65 Further examples are inhibitors of EGFR,
HER2 and HER3, depending on the tumour type and
location. In a recent basket clinical trial, not all
tumours were affected by the same HER mutations,
and response to the HER2 inhibitor (neratinib) var-
ied in different tissues: for example, colorectal or
bladder cancer with HER2 mutations did not
respond.66 In summary, specific drug treatment
depends on the tissue context.34
Assessment and validation of molecular subtypes by
protein expression
Molecular classification based on mRNA expression
profiling of gene groups is a frequent approach to
identify and classify molecular subtypes of tumours.
One of the major achievements of molecular classifi-
cation has been the subcategorisation according to
prognosis, and it is instrumental for the identification
of new genetic alterations. However, mRNA-based
expression studies are often limited by a low repro-
ducibility, depending on mRNA stability. Further-
more, single-cell sequencing approaches are not
Pylocytic Astrocytoma
















Figure 1. Genetic alterations such as BRAF mutations can be detected in many different tumours. Importantly, the biological meaning and
the response to specific BRAF inhibitors depend on tumour type and tissue localisation.
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feasible in routine diagnostics. Currently, samples are
sequenced as the bulk of tumour cells and therefore
do not provide information on ITH. In addition to these
technical issues, monitoring gene expression at the
mRNA level does not necessarily correlate with the
function of a protein within a cell, as many post-tran-
scriptional modifications determine whether or not
mRNA finally gives rise to a functional protein. Impor-
tantly, however, the different molecular subtypes based
on enormous mRNA expression matrices can be vali-
dated according to protein or gene expression using
just a few in-situ hybridisation or IHC probes in most
molecular cancer subtypes (see Table 2).
Breast carcinoma. According to the mRNA expression
profile, six molecular subtypes are described: luminal A,
luminal B, HER2+, basal-like, claudin-low and normal
breast-like.67,68 However, RNA signatures can vary
dramatically between patients with the same molecular
subtype69 and, with the exception of the basal subtype,
are not highly reproducible for diagnosis on microarray
analysis.67,70,71 A high degree of ITH has been
described, as assessed by immunohistochemical (IHC)
studies,72 array-CGH studies71 and massive parallel
sequencing technologies.73 Given these problems in the
exact diagnosis of breast cancer subtype by molecular
characterisation, IHC-based characterisations are
recommended as a diagnostic approach in most of the
consensus oncology guidelines.74 Additional IHC
staining helps to distinguish luminal A and B subtypes,
such as GATA3 and FOXM.75 CK5 and EGFR expression
define the basal subtype of breast cancer,76 and CD44
and Snail expression determine the claudin-low
subtype.77 Finally, the normal breast-like subtype is
defined by low expression of the above-mentioned
markers and expression of factors such as CD36 in a
low-grade histological tumour.78
Colorectal carcinoma. Molecular subtypes of colorectal
carcinoma have been distinguished by genomic,
epigenetic and transcriptomic parameters.79,80 Four
different colorectal carcinomas, CMS1–4, have been
described according to immunohistochemistry. The
molecular subtypes can be identified as mesenchymal
type (CMS4), which has the worst prognosis, immune
type (CMS1) and epithelial subtypes (CMS2/3), based
on four proteins: CDX2, FRMD6, HTR2B and ZEB1.
In all subtypes, the drivers and actionable genes must
be studied according to approved protocols (e.g. RAS,
BRAF).81,82
Lung carcinoma. Three molecular subtypes have been
described based on DNA methylation [high,
intermediate or low CpG island methylator phenotype
(CIMP)], transcriptomics and RNA array: proximal
proliferative, proximal inflammatory and terminal
respiratory unit.83 Recently, using an integrative
analysis with all available omics data, six different
molecular subtypes have been described.84 Protein
markers to distinguish those subtypes are still under
way and that classification is not used in clinical
oncology guides.
Nevertheless, druggable genetic alterations can be
observed in the different molecular subtypes, and cur-
rent oncology guidelines follow a reasonable scheme
based on druggable genes, combining polymerase
chain reaction (PCR)-based methods to identify EGFR
and BRAF mutations, and in-situ hybridisation or
immunohistochemistry for the expression of BRAF
V600E, ALK, ROS, HER2, RET and MET.
Glioblastomas. Four molecular subtypes have been
described based on gene expression profile: proneural,
mesenchymal, mixed and unknown,85 and up to six
based on methylation arrays, recurrent driver genes
and transcriptomics, by the DKFZ (Deutsches
Krebsforschungs-zentrum).86–89 These molecular
subtypes are used currently in clinical oncology guides.
In brief, according to the most recent World Health
Organisation (WHO) classification,90 grade IV gliomas
are classified as IDH-mutant GB, IDH-wt GB and
midline glioma with H3 K27M mutation. In order to
discriminate between subtypes the following can be
analysed using IHC, fluorescence in-situ hybridisation
(FISH) or PCR: IDH1/IDH2, ATRX, TP53, FGFR, NF1,
H3.1 and H3.3 mutations, EGFR and PDGFR
amplifications, BRAF V600 mutation or translocations
and CDKN2A/CDKN2B deletion.
Medulloblastomas. Medulloblastomas have four molec-
ular subtypes with clear clinical differences (group 1
WNT activated; group 2 SHH activated; group 3 or
GABAergic; and group 4 or glutaminergic). These sub-
types can be assessed by immunohistochemistry or FISH,
studying b-catenin, GAB1, YAP1, Filamin A, p53, Glki1,
17q+ (group 3), MYC and CDK6 amplification.91–94
Endometrial carcinoma. Two types of endometrial
carcinoma have been described based on a combination
of epidemiological, clinical, histological and molecular
genetic data, distinguishing type I endometrioid
endometrial carcinoma (EEC) and type II non-
endometrioid endometrial carcinoma (NEEC).95 A
molecular classification of EC has been proposed based
on The Cancer Genome Atlas Research Network
(TCGA) study, published in 2013. TCGA analysis
© 2019 Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 75, 4–19.
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revealed four tumour groups:96 group 1, EEC with
somatic inactivating mutations in POLE exonuclease
and very high mutation rates (hypermutated) (7%);
group 2, EEC with microsatellite instability (MSI),
frequently with MLH-1 promoter hypermethylation
and high mutation rates (28%); group 3, EEC with low
copy number alterations (39%), also called EEC with no
specific molecular profile; and finally, group 4 (serous-
like or copy-number high) (26%), with a low mutation
rate but frequent TP53 mutations. These four types
show different clinical, pathologic and molecular
features.
Urothelial bladder carcinoma. Different molecular
classifications are currently being explored. One of
them, based on RNA genomewide studies, has
characterised two main molecular groups of bladder
cancer with prognostic and predictive impact.97
Group 1 basal subtype includes a subgroup of
claudin-low and is characterised by expression of the
Table 2. Molecular signatures detected by IHC and FISH analysis in FFPE tumour samples
Tumour type Molecular signature Classification Immunohistochemistry FISH
Breast cancer Luminal A ER+, PR+, GATA+, FOXM+, Ki67 <15%
Luminal B ER+, PR+, GATA+, FOXM+, Ki67 >15%
HER2 enriched ER, PR, HER2+ ERB2 ampl.
Basal-like ER, PR, HER2, CK5+, EGFR+
Claudin low ER, PR, HER2, CD44+, Snail+
Normal breast-like ER, PR, HER2, CD36+
Colon cancer CMS1 (immune) FRMD6, HTR2B, ZEB1, CDX2+
CMS2 FRMD6, HTR2B, ZEB1, CDX2+
CMS3 FRMD6, HTR2B, ZEB1, CDX2+
CMS4 (mesenchymal) FRMD6+, HTR2B+, ZEB1+ CDX2
Glioblastomas Proneural IDH mut, p53mut, OLIG2 PDGFRA ampl, CDK4 ampl,
CDK6 ampl
Mesenchymal CD44, NF1 EGFR ampl
Classical EGFR vIII mut, p53 EGFR ampl, loss of PTEN
and CDKN2A
Neural –
Medulloblastoma WNT-activated b-Catenin nuclear, GAB1, YAP1+, Filamin A+ Monosomy chr. 6
SHH-activated, TP53-WT b-Catenin cyto, GAB1+, YAP1+, Filamin A+ GLKi1 ampl, PTCH1 del
SHH-activated, TP53-mut b-Catenin cyto, GAB1+, YAP1+, Filamin A+, p53+ MYCN ampl,
CLI2 ampl, 17p loss
Group 3 (Gabaergic) b-Catenin cyto, GAB1, YAP1, Filamin A 17q ampl
Group 4 (Glutaminergic) b-Catenin cyto, GAB1, YAP1, Filamin A MYC ampl, CDK6 ampl
Endometrial Ultramutated (POLE)
Hypermutated (MSI) MMRd (MLH1)
Copy number low
Copy number high P53+
IHC, Immunohistochemistry; FISH, Fluorescence in-situ hybridisation; FFPE, Formalin-fixed paraffin-embedded.
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basal cytokeratins CK5, CK14 and CD44. Group 2
luminal subtype has mutations of the fibroblast
growth factor receptor 3 (FGFR3) gene and urothelial
differentiation markers such as CK20, GATA3 and
uroplakins. The luminal subtype has a more
favourable prognosis than the basal subtype.97
Recently, a prospective multicentre validation study
with a 12-gene signature progression score in non-
muscle-invasive bladder cancer was demonstrated to
have independent prognostic power beyond clinical
and histopathological risk factors, and could help in
stratifying patients to optimise treatment and follow-
up.98 Other molecular alterations have also been
described, such as FGFR3 mutations in 80%,99
PI3KCA mutations in approximately 20% and
mutations in the core promoter region of the human
telomerase reverse transcriptase (TERT) gene in up to
85% of bladder tumours. Interestingly, FGFR3 and
PIK3CA mutations have been demonstrated as
biomarkers on liquid biopsy for disease surveillance
for bladder cancer.100 Different cell cycle genes may
be altered in invasive urothelial carcinoma, mainly
tumour suppressor genes, including TP53, p16 and
Rb.101 Finally, combinations of TP53, p21, p27 and
pRb proved to be more precise in classifying bladder
cancer patients into risk groups.102
G E N E E X P R E S S I O N H E T E R O G E N E I T Y A N D
E N V I R O N M E N T A L C E L L S
mRNA expression versus protein expression
Molecular tumour subtypes based on mRNA expres-
sion profiles often show discordance with protein
expression levels, depending on the RNA stability and
the area sampled. It is well known that RNA studies
are problematic regarding reproducibility, and that
protein expression shows the real functional status of
the targets. A classic example is breast cancer, in
which mRNA profiles can define at least six different
molecular categories. While this can be used as a
general classification scheme, only IHC or FISH anal-
ysis of proteins in tumour cells within the individual
subgroup can provide the exact diagnosis to guide
treatment and prognosis. Some reports67 describe dis-
cord, when comparing mRNA and protein expression
levels, of up to 50% of cases in HER2 status, and in
more than 15% of cases when distinguishing between
luminal A and luminal B.
Tissue-specific protein expression profiles
The relation between tissue context and protein
expression has recently been reported in an extensive
gene expression study of 17 different tumour types in
more than 8000 patients.103 The study encompassed
massive studies of sequencing, mRNA expression, pro-
tein expression and engaged databases from the
TCGA and the Human Protein Atlas. The authors
also carried out in-depth bioinformatics and systems
biology analysis. Interestingly, more than 2700 genes
correlated with prognosis, showing opposite prognos-
tic effects depending on tumour type and location.
Within the genes associated with worse prognosis,
two groups were described. The first group comprised
genes related to cell proliferation, of which more than
190 were identified (of the 314 described related to
the cell cycle). This gives an idea of the great redun-
dancy of gene alterations, especially the level of
expression that may exist depending on tumour type.
The second group comprised genes associated with
tissue differentiation and their prognostic correlation.
This is a point that has always been described in
pathology, distinguishing tumours with a low degree
of malignancy, i.e. histologically better differentiated,
from those with a high degree of malignancy, i.e.
poorly differentiated with a higher degree of cellular
atypia. The study also found that more than 50% of
the genes associated with prognosis were not related
to Hanahan and Weinberg’s classic hallmarks.6
Therefore, one of the conclusions was the enormous
variation in gene expression profiles, both at an inter-
and intratumour level. They described new sets of
genes that, according to their expression, were associ-
ated with prognosis in the different tumour types,
underlining the clinical importance and the validity
of protein expression versus mRNA or genetic alter-
ations. For example, in lung carcinoma, they pro-
posed a prognostic correlation with the expression of
the genes ERO1A, S100A16, S100A6, MKi67,
SLC2A1, TACC3, ANLN, and CADM1.103–105
Assessment of intratumour heterogeneity based on protein
expression
Currently, the most robust readout for ITH assessment
comes from IHC. A classic example is ITH of oestrogen
receptors, which may be positive in just 1% of cells; in
fact, this ITH has been reported to be associated with
long-term risk of fatal breast cancer.106 Other exam-
ples are the heterogeneous expression of cyclin D1 in
mantle cell lymphomas, which otherwise carry a
homogeneous CCND1–IGH translocation107 and the
subtype of HER2+ breast or gastric tumours that can
range from 10% to 100% positive cells.9,108
Within an entire tumour, protein expression often
depends on local factors such as hypoxia, nutrient
starvation or oxidative stress, independently of the
cell’s genetic background. These environmental cues
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can alter entire signalling pathways downstream of
well-established oncogenic alterations.109 Many
tumours may have activating mutations in the most
upstream elements of certain signalling cascades,
such as RAS, EGFR and HER2, but phosphorylation
of downstream factors such as MAP-kinases or mTOR
may be inhibited by environmental factors;110 there-
fore, even if specific driver genetic alterations are
inhibited, no effect will be observed in cells in which
these signalling pathways are inhibited by such fac-
tors.109,111
Evaluation of heterogeneity in immune checkpoints and
inflammatory cells
Primary tumours have heterogeneous epithelial cell
content, and form an ecosystem with the environ-
mental cells, including stromal cells, endothelial cells,
leucocytes, lymphocytes, histiocytes and their secreted
factors. In a pathological context, we can quantify
and evaluate the expression of the immune check-
points programmed cell death ligand 1 (PD-L1) and
programmed cell death-1 (PD-1) in epithelial and
inflammatory parts of the tumour and use this infor-
mation for clinical correlation studies. Similar to cell
signalling pathways, key components of immune
checkpoints, such as PD-L1, can also have heteroge-
neous expression throughout the tumour.112 The PD-
L1 protein is expressed in a wide range of cell types,
including lymphocytes, macrophages and dendritic
cells, and is stimulated by variable and complex
mechanisms. In contrast to other immune checkpoint
components, PD-L1 is rarely expressed in normal tis-
sue but is induced in tumour-associated tissue, is a
tumour biomarker and is also an attractive drug tar-
get.113,114 As many current treatment schemes are
based on immunotherapy, pathological assessment
should include immune checkpoint proteins. Further-
more, the heterogeneous and dynamic expression of
factors such as PD-L1 in basal conditions and in
response to different treatments presents a challenge
to predicting which patients will respond to anti-
PDL1 therapies. The assessment of CD4+, CD8+ cells,
and tumour mutational burden (TMB) can also be
helpful in clinical decision-making. TMB has recently
been proposed as a new biomarker to quantify the
potential tumoral neoantigenicity, with the aim of
predicting patients who will benefit from
immunocheckpoint inhibitors. Nevertheless, different
technologies and different thresholds have been pro-
posed to define high versus low TMB in different tis-
sue samples.115–117
Finally, the role of the microenvironment in car-
cinogenesis is gaining importance, although in small
biopsies it is impossible to integrate the role of leuco-
cytes, stromal cells and lymphocytes and the assess-
ment of immune checkpoints.
Discussion
T H E S O L U T I O N : T O I N T E G R A T E C L I N I C A L ,
R A D I O L O G I C A L , M O L E C U L A R A N D E X P R E S S I O N
D A T A W I T H I N A T I S S U E C O N T E X T
We postulate that cancer formation is a consortium of
tumour cell clones, microenvironmental cells and local
stressors (such as hypoxia) that alter protein expres-
sion and enhance tumour heterogeneity. Therefore, we
believe that cancer must be considered within the con-
text of tissue type. The correct diagnosis of a tumour
should assimilate the clinical, radiological, histopatho-
logical, molecular and proteomic data.
As intratumour protein and molecules are highly
heterogeneous and diagnostic biopsies are small, we
envision that correlation with radiological imaging
and nuclear medicine will be crucial to select areas
that are more representative of the whole tumour.
Determination of the exact histological type is cru-
cial for an exact diagnosis; for example, in lung carci-
noma there is a huge difference in prognosis and
treatment between diagnoses of small-cell carcinoma,
adenocarcinoma or large-cell carcinoma. Similarly, in
ovarian carcinoma, prognosis and survival varies
widely between types: high- or low-grade serous car-
cinoma, endometrioid carcinoma, clear-cell carci-
noma or mucinous adenocarcinoma. Most tumours
can be diagnosed according to histological criteria as
high- or low-grade. The distinction is based on the
degree of cell differentiation, the intensity of cellular
atypia and cell proliferation. A proliferation index,
such as Ki67, can be used to quantify the percentage
of replicative cells within a tumour. This simple pro-
tein can be detected regardless of which genetic
alterations are inducing the proliferation. The above-
mentioned classical factors have all been validated by
RNA and molecular data.103
Identification of master genes and funnel factors
As described above, cellular stress can alter gene
expression in tumour cells at several levels modifying
biochemical signalling pathways and feedback
loops,111 and protein expression can be heterogenous.
While these biochemical changes are restricted to cer-
tain areas within the tumour, funnel factors such as
p4E-BP1 and peIF4E are usually expressed evenly
throughout the tumour, regardless of the upstream
oncogenic alterations and local environmental
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changes. The search for cellular targets expressed in
most areas of tumours is becoming crucial to over-
come tumour heterogeneity.
Because of the huge amount of data and complex
positive and negative feedback regulating the final
signal and the biological effect, systems biology is
becoming essential for the understanding and identifi-
cation of the real nodes or factors which are drivers
in specific tumours in individual patients. The proto-
oncogene myc in Burkitt lymphoma and the canoni-
cal nuclear factor kappa B heterodimer in diffuse
large B cell lymphoma are classic examples of so-
called master genes.118–120
Advances in digital pathology
Advances in digital pathology (whole slide imaging)
now allow interpretation of digital slides on computer
stations and integration of molecular features into
the microscopic context. The differential expression of
genes in different areas of the tumour can be inter-
preted precisely, and haematoxylin and eosin-stained
microscopic sections can be merged with multiple
immunohistochemical stains for different proteins.
Digital pathology also allows tumour annotation for
microdissection for different tumour components,
with appropriate cellularity assessment of tumour ele-
ments and the non-neoplastic microenvironment.
Digital pathology is essential to establish comput-
erised algorithms to correlate molecular alterations
with tumour phenotype.
Tissue-specific multiplex technology
Given the numerous alterations in genes, protein
expression and mRNA, it is clear that we will have to
implement multiplex technologies that will allow us
to study multiple factors simultaneously on the same
histological sections. With this approach we can min-
imise the amount of tissue needed for molecular and
protein studies and for quantification of the expres-
sion of different factors and their inter-relationship.
Different platforms are emerging, with different quan-
titative multispectral fluorescence approaches, or with
mass spectrometry in situ, to allow the study and
quantification of several dozen markers. Also, new
next-generation sequencing technologies are being
implemented in routine testing combining DNA and
RNA analysis from the same slide reducing the
amount of tissue and also the ITH.121,122
An interpretative and holistic data assessment with ‘deep
learning’ (artificial intelligence with automatic learning)
The main objective for the use of deep learning in
pathology is to improve existing algorithms for
biomarker quantification and to develop smart and
robust algorithms. It can be based on three main
areas or objectives: (i) tumour type classification, (ii)
tumour prognosis (prediction system, learning from
experience) and (iii) personalised treatment allocation
system (also a reinforcement learning system). In fact,
deep learning is already being applied in various
tumour types, including breast, lung, melanoma and
glioblastoma.123–126 The integration of such informa-
tion and algorithms into everyday clinical practice
can help to minimise subjective evaluations and
improve the precise diagnosis for each tumour and
patient (see Figure 2).
Systems biology encompasses tools that hold great
promise for deciphering the vulnerabilities of the
tumour ecosystem as a whole. Studies are based on
the premise that multiple oncogenic events converge
on a number of cellular networks that may contain
essential or synthetically lethal clinically targetable
hubs or factors,127,128 such as the eIF4F complex.
Nonetheless, many contemporary systems biology
approaches do not consider intratumour heterogene-
ity. This is relevant because key functional nodes
within the metabolic, signal transduction and gene
expression networks responsible for supporting the
tumour phenotype are critically dependent on the
heterogeneity of the tumour. These data can also help
to classify tumours according to histopathological,
biochemical and genomic features and thus help to
tailor the diagnosis and clinical management to a
patient’s biological tumour profile. Accordingly, mul-
tidimensional molecular and gene expression data,
which are associated with the response to antitumour
treatments and clinical progress, are thought to facili-
tate the selection of patients who are more likely to
respond to targeted or ‘precise’ therapies.129–131 The
availability of systemwide data in a variety of cancers
is facilitating the development of approaches that go
beyond the classic, reductionist paradigms that asso-
ciate single genes with cellular phenotypes and func-
tions. Systems biology approaches consider the
interplay between multiple molecular factors that
underpin phenotype development. Accordingly, rather
than a genetic disease, cancer is now perceived as a
disease of ‘networks’,131 and to fully grasp the com-
plexity of the tumour ecosystem the networks driving
cancer need to be mapped and their dynamics and
evolution over time deciphered. Emerging data show
that these cancer networks are constantly rewired in
part by clonal interactions, changing microenviron-
ments and the acquisition of novel molecular alter-
ations that are largely induced by anticancer
treatments.127,132 Therefore, minor subpopulations
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that are not readily detectable in bulk tumours or
that can adapt to hostile environments may emerge
following treatments that specifically target cancer-
driving mutations present in the predominant tumour
subpopulations. Thus, in the coming years, systems
biology implementation may be crucial for (i)
detailed, clinically oriented subclassification of cancer
types, (ii) mapping of oncogenic networks and identi-
fication of the critical nodes to overcome the effects of
ITH and (iii) informing future preclinical research
and design of Phase I clinical trials by anticipating
therapy response in silico and predicting the best tar-
gets for each patient and tumour (personalised cancer
therapy or precision medicine).
Liquid biopsies
As biopsies are associated with a degree of invasive-
ness and cannot always be repeated, new approaches
have been proposed, such as the analysis of circulat-
ing tumour cells (CTCs), plasma-derived cell-free
tumour DNA (cfDNA) or RNA and, more recently,
DNA from circulating tumour exosomes in blood.133–
135 This strategy enables a global assessment of the
constellation of somatic genetic alterations in a
tumour irrespective of its anatomical location, and is
becoming a good alternative for the study of a
tumour mutational landscape in situations where
biopsies or surgical samples are difficult to obtain.
Hence, liquid biopsy appears to be a very relevant
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Figure 2. Schematic representation of the potential use of artificial intelligence (AI) in the diagnosis of melanoma. All information (clinical features,
histology, molecular alterations, other parameters) are analysed through AI establishing different algorithms resulting in a more precise diagnosis.
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tool for the identification of potential actionable geno-
mic alterations and therapeutic targets, monitoring
treatment response, predicting disease progression
before clinical and radiological confirmation and iden-
tifying mechanisms of resistance in the particular
context of patients with early-stage and metastatic
disease.136,137 Furthermore, liquid biopsy provides
additional cues on ITH, as reported in a recent pilot
study in patients with early-stage NSCLC.138
Conclusion
Tumours show such a degree of morphological,
molecular and proteomic heterogeneity, and a close
relationship with microenvironmental factors, that
for the accurate pathological evaluation of tumours
an integrated approach seems essential: all genomic
and proteomic data should be evaluated taking into
account the heterogeneity and tissue type (Figure 3).
We propose the integration of all such factors, along
with the classical pathological factors, within the
context of the tissue; we call this approach tissu-
nomics.
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